Results 21 to 30 of about 4,681 (114)

Novel CFTR Modulators for Treating Cystic Fibrosis [PDF]

ACS Medicinal Chemistry Letters, 2021
openaire   +3 more sources

Cystic Fibrosis: Treatment with CFTR Modulators

, 2023
CFTR modulators have been a groundbreaking new invention starting with the approval of the CFTR corrector Ivacaftor in 2012. Nowadays, up to 90% of CF patients have the potential ability to get treated by an appropriate CFTR modulator. Ivacaftor showed significant improvement in the treatment of CF patients with gating mutations, especially in G551D ...
openaire   +2 more sources

The gut-lung axis in the CFTR modulator era. [PDF]

Front Cell Infect Microbiol, 2023
Lussac-Sorton F, Charpentier É, Imbert S, Lefranc M, Bui S, Fayon M, Berger P, Enaud R, Delhaes L.   +8 more
europepmc   +1 more source

The PROSPECT Is Bright for CFTR Modulators

Annals of the American Thoracic Society, 2021
Kristina Montemayor, Noah Lechtzin
openaire   +2 more sources

Effect of CFTR Modulators on Oxidative Stress and Autophagy in Non-CFTR-Expressing Cells

International Journal of Molecular Sciences
The triple combination therapy for cystic fibrosis (CF), including elexacaftor, tezacaftor and ivacaftor (ETI or Trikafta), has been shown to improve lung function and reduce pulmonary exacerbations, thereby enhancing the quality of life for most CF patients.
Scialò, Filippo, Cernera, Gustavo, Polise, Lorenza, Castaldo, Giuseppe, Amato, Felice, Villella, Valeria Rachela   +5 more
openaire   +3 more sources

Increased aminotransferases do not necessarily mean hepatotoxicity of CFTR modulator therapy. [PDF]

Clin Exp Hepatol, 2023
Woynarowski M, Sapiejka E, Jóźwiak M, Wierzbicka-Rucińska A.   +3 more
europepmc   +1 more source

Hypoglycaemia after Initiation of CFTR Modulator Therapy in a Cystic Fibrosis Patient without Diabetes. [PDF]

Case Rep Endocrinol, 2023
Yskout M, Vliebergh J, Bor H, Dupont L, Lorent N, Van Bleyenbergh P, Gillard P, Van der Schueren B, Mertens A, Mathieu C, Vangoitsenhoven R.   +10 more
europepmc   +1 more source

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform. [PDF]

Front Pediatr, 2023
Yaacoby-Bianu K, Cohen-Cymberknoh M, Shoseyov D, Lavi T, Ostrovski A, Shteinberg M, Livnat G.   +6 more
europepmc   +1 more source

Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis. [PDF]

Int J Mol Sci, 2023
Graeber SY, Balázs A, Ziegahn N, Rubil T, Vitzthum C, Piehler L, Drescher M, Seidel K, Rohrbach A, Röhmel J, Thee S, Duerr J, Mall MA, Stahl M.   +13 more
europepmc   +1 more source

RFFL antisense oligonucleotides: A novel stabilization strategy to broaden the reach of CFTR modulator therapy. [PDF]

Mol Ther Nucleic Acids
Pedemonte N.
europepmc   +1 more source